Donor-specific antibodies in renal allograft recipients. A reevaluation of the 51Cr-release assays comparing fibroblast and lymphoid target cells.
Donor-specific alloantibody was monitored in recipients of 81 renal allografts by 51Cr release assays. Complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity were both followed. In addition to the conventional lymphoid target cells nonlymphoid target cells, namely fibroblasts from the donor, were used. Although antibody against donor lymphoid cells was found more frequently, associations with graft loss and with rejection were greater with antibody against fibroblasts. The superior association of antibody against fibroblasts with clinical events suggests that wider use of nonlymphoid target cells would be of value in studies of alloantibody responses in renal transplant recipients.